StockNews.com downgraded shares of Pediatrix Medical Group (NYSE:MD – Free Report) from a hold rating to a sell rating in a research note released on Monday.
A number of other equities analysts have also recently weighed in on MD. Jefferies Financial Group reduced their price target on Pediatrix Medical Group from $10.00 to $9.00 and set a hold rating for the company in a report on Wednesday, March 6th. Deutsche Bank Aktiengesellschaft raised Pediatrix Medical Group from a sell rating to a hold rating and set a $8.00 target price for the company in a research note on Friday, June 7th. Finally, Truist Financial reissued a hold rating and issued a $10.00 price target on shares of Pediatrix Medical Group in a research note on Wednesday, May 15th. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. According to MarketBeat, the company presently has an average rating of Hold and a consensus price target of $9.10.
Get Our Latest Stock Report on Pediatrix Medical Group
Pediatrix Medical Group Stock Performance
Pediatrix Medical Group (NYSE:MD – Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.15 by $0.02. The company had revenue of $495.10 million for the quarter, compared to analyst estimates of $496.25 million. Pediatrix Medical Group had a negative net margin of 3.53% and a positive return on equity of 10.31%. As a group, analysts predict that Pediatrix Medical Group will post 1.13 earnings per share for the current year.
Institutional Trading of Pediatrix Medical Group
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Boston Partners raised its stake in Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares during the period. Virtu Financial LLC purchased a new stake in shares of Pediatrix Medical Group during the 1st quarter valued at approximately $124,000. Tidal Investments LLC acquired a new position in Pediatrix Medical Group in the first quarter valued at approximately $442,000. Price T Rowe Associates Inc. MD grew its position in Pediatrix Medical Group by 4.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 87,369 shares of the company’s stock worth $877,000 after acquiring an additional 3,669 shares during the period. Finally, Vanguard Group Inc. increased its stake in Pediatrix Medical Group by 1.6% during the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after acquiring an additional 164,333 shares during the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.
Pediatrix Medical Group Company Profile
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Further Reading
- Five stocks we like better than Pediatrix Medical Group
- Airline Stocks – Top Airline Stocks to Buy Now
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Market Cap Calculator: How to Calculate Market Cap
- Progress Software Stock Back in the Green After Beating Forecasts
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.